In lung cancer, the BTK inhibitor ibrutinib effectively inhibits the proliferation of some epidermal growth factor receptor (EGFR) mutant lung cancer cells by inhibiting the autophosphorylation of EGFR [23]. The gene discussed is BTK; the disease is lung cancer.